USPTO serial 99503974
PRIMEBODY
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- NISHIGAYA, CHRISTINE EIKO
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with PRIMEBODY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gayani R Weerasinghe
Gayani R Weerasinghe Law Office of Gayani R. Weerasinghe, APC.325 W Washinton St, Ste 2-3013San Diego, CA 92103United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of cancer, immune-related, autoimmune, metabolic, and inflammatory diseases; therapeutic pharmaceuticals for the treatment of cancer, immune-related, autoimmune, metabolic, and inflammatory diseases; pharmaceutical preparations, namely, a pro-drug being a drug delivery system comprising biologics in the form of masked antibody and protein compounds for intravenous administration that facilitate conditional activation release of tissue and tumor targeting pharmaceuticals; diagnostic agents, preparations, and substances for medical purposes; therapeutic agents, preparations, and substances for medical purposes, namely, masked antibodies and proteins in the form of therapeutic biological preparations for use in the treatment of cancer, immune-related disorders, autoimmune diseases, metabolic and cardiometabolic disorders; pharmaceutical preparations and substances for the treatment of cancer, immune-related disorders, autoimmune diseases, metabolic and cardiometabolic disorders, and inflammatory conditions in the field of oncology, immunology, autoimmune, metabolic, and inflammatory diseases; diagnostic agents and preparations in the nature of biochemical reagents for medical purposes | ACTIVE | — |
| 042 | Scientific and technological services, namely, research and development in the fields of pharmaceuticals, biotechnology, and medical diagnostics namely, preparations, biologics, and diagnostic agents; development of pharmaceutical drugs for oncology, immunology, autoimmune, metabolic, and inflammatory diseases, conditionally-activated and tumor-activated therapeutics and biologics; Pharmaceutical research and development services relating to the treatment of cancer, immune-related, autoimmune, metabolic, and inflammatory diseases using proprietary conditional antibody technology for the design, development, testing, and validation of pharmaceutical substances and drug candidates; conducting clinical and pre-clinical research being scientific research in the nature of conducting clinical trials for others relating to pharmaceuticals and biotechnology in the fields of immunotherapy, immune-modulating therapy, oncology, immunology, autoimmune, metabolic, and inflammatory diseases; pharmaceutical research and development relating to the treatment of cancer, immune-related, autoimmune, metabolic, and inflammatory diseases; providing scientific information in the field of pharmaceutical, biotechnological, and clinical research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Voro Therapeutics, Inc.
- Other trademarks owned by Voro Therapeutics, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named PRIMEBODY
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 20, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 25, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 25, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 19, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 27, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 27, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 27, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 9, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 9, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 9, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 15, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 15, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 15, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 12, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 19, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 19, 2025 | NWAP | NEW APPLICATION ENTERED | — |